摘要
免疫检查点抑制剂已广泛应用于肿瘤治疗,尽管其耐受性通常优于化疗,但可引起免疫相关不良反应。其中免疫检查点抑制剂相关肺炎(immune checkpoint inhibitor⁃related pneumonitis,CIP)具有较高的病死率,循证医学证据不多,且诊治经验有限。文章结合国内外指南、专家共识和研究,对CIP尤其是激素难治性CIP的治疗进展作一综述。
Immune checkpoint inhibitors have been widely used in cancer treatment.Although they are generally better tolerated than chemotherapy,they can cause immune⁃related adverse events.Among these,immune checkpoint inhibitor⁃related pneumonitis(CIP)has a relatively high mortality rate,with limited evidence from evidence⁃based medicine and limited experience in diagnosis and treatment.This article reviews the therapeutic advancements in CIP based on domestic and international guidelines,expert consensus,and relevant studies,with particular focus on the treatment progress of steroid⁃refractory CIP.
作者
陶媛
季辰菲
吉宁飞
TAO Yuan;JI Chenfei;JI Ningfei(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)
出处
《南京医科大学学报(自然科学版)》
北大核心
2025年第5期737-744,共8页
Journal of Nanjing Medical University(Natural Sciences)
基金
南京医科大学⁃齐鲁临床研究基金(2024KF0266)。
